Testosterone deficiency in testicular germ-cell cancer patients is not influenced by oncological treatment

International Journal of Andrology

Volumn 34, Issue 5 PART 2, 2011, Pages

  Puhse G ^a   Secker, A ^a   Kemper, S ^a   Hertle, L ^a   Kliesch, S ^a  

^a UNIVERSITY HOSPITAL MÜNSTER   (Germany)

Author keywords

Androgen deficiency; Chemotherapy; Orchiectomy; Testis cancer; Testosterone

Indexed keywords

BLEOMYCIN; CARBOPLATIN; CISPLATIN; ETOPOSIDE; IFOSFAMIDE; TESTOSTERONE;

ADULT; ANDROGEN DEFICIENCY; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURGERY; GERM CELL TUMOR; HUMAN; LONGITUDINAL STUDY; LYMPH NODE DISSECTION; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; ORCHIECTOMY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; SEMINOMA; TESTIS CANCER; TESTIS GERM CELL CANCER; TESTIS NONSEMINOMA CANCER; TESTIS SIZE; TESTOSTERONE BLOOD LEVEL;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; HUMANS; LONGITUDINAL STUDIES; MALE; NEOPLASMS, GERM CELL AND EMBRYONAL; PROSPECTIVE STUDIES; SEMINOMA; TESTICULAR NEOPLASMS; TESTIS; TESTOSTERONE;

EID: 80053384082     PISSN: 01056263     EISSN: 13652605     Source Type: Journal    
DOI: 10.1111/j.1365-2605.2010.01123.x     Document Type: Article

References (44)

1. Anawalt BD & Merriam GR. (2001) Neuroendocrine aging in men: andropause and somatopause. Endocrinol Metab Clin North Am 30, 647-669.
2. Araujo AB, Esche GR, Kupelian V, O'Donnell AB, Travison TG, Williams RE, Clark RV & McKinlay JB. (2007) Prevalence of symptomatic androgen deficiency in men. J Clin Endocrinol Metab 92, 4241-4247.
3. Berger CC, Bokemeyer C, Schuppert F & Schmoll HJ. (1996) Endocrinological late effects after chemotherapy for testicular cancer. Br J Cancer 73, 1108-1114.
4. Brennemann W, Stoffel-Wagner B, Helmers A, Mezger J, Jager N & Klingmüller D. (1997) Gonadal function of patients treated with cisplatin based chemotherapy for germ cell cancer. J Urol 158, 844-850.
5. Cohen PG. (2001) Aromatase, adiposity, aging and disease. The hypogonadal-metabolic-atherogenic-disease and aging connection. Med Hypotheses 56, 702-708.
6. DeSantis M, Albrecht W, Holtl W & Pont J. (1999) Impact of cytotoxic treatment on long-term fertility in patients with germ-cell cancer. Int J Cancer 83, 864-865.
7. Dörnberger V, Dörnberger G & Eggstein M. (1986) Volumetry of the testis using real-time sonography. Ultraschall Med 7, 300-303.
8. Feldman HA, Longcope C, Derby CA, Johannes CB, Araujo AB, Coviello AD, Bremner WJ & McKinlay JB. (2002) Age trends in the level of serum testosterone and other hormones in middle-aged men: longitudinal results from the Massachusetts Male Aging Study. J Clin Endocrinol Metab 87, 589-598.
9. Fossa SD & Kravdal O. (2000) Fertility in Norwegian testicular cancer patients. Br J Cancer 82, 737-741.
10. Fossa SD, Aabyholm T, Vespestad S, Norman N & Ous S. (1993) Semen quality after treatment for testicular cancer. Eur Urol 23, 172-176.
11. Gerl A, Muhlbayer D, Hansmann G, Mraz W & Hiddemann W. (2001) The impact of chemotherapy on Leydig cell function in long term survivors of germ cell tumors. Cancer 91, 1297-1303.
12. Gietema JA, Meinardi MT, Messerschmidt J, Gelevert T, Alt F, Uges DR & Sleijfer DT. (2000) Circulating plasma platinum more than 10years after cisplatin treatment for testicular cancer. Lancet 355, 1075-1076.
13. Godfrey K. (1992) Comparing the means of several groups. In: Medical Uses of Statistics, 2nd edn (eds JC Bailar & F Mosteller), pp. 233-257. NEJM Books, Boston.
14. Gray A, Feldman HA, McKinlay JB & Longcope C. (1991) Age, disease, and changing sex hormone levels in middle-aged men: results of the Massachusetts Male Aging Study. J Clin Endocrinol Metab 73, 1016-1025.
15. Greenfield DM, Walters SJ, Coleman RE, Hancock BW, Eastell R, Davies HA, Snowden JA, Derogatis L, Shalet SM & Ross RJ. (2007) Prevalence and consequences of androgen deficiency in young male cancer survivors in a controlled cross-sectional study. J Clin Endocrinol Metab 92, 3476-3482.
16. Harman SM, Metter EJ, Tobin JD, Pearson J & Blackman MR. (2001) Longitudinal effects of aging on serum total and free testosterone levels in healthy men. Baltimore Longitudinal Study of Aging. J Clin Endocrinol Metab 86, 724-731.
17. Heaton JP & Morales A. (2001) Andropause - a multisystem disease. Can J Urol 8, 1213-1222.
18. Howell SJ & Shalet SM. (2002) Effect of cancer therapy on pituitary-testicular axis. Int J Androl 25, 269-276.
19. Huddart RA, Norman A, Moynihan C, Horwich A, Parker C, Nicholls E & Dearnaley DP. (2005) Fertility, gonadal and sexual function in survivors of testicular cancer. Br J Cancer 93, 200-207.
20. Jacobsen KD, Theodorsen L & Fossa SD. (2001) Spermatogenesis after unilateral orchiectomy for testicular cancer in patients following surveillance policy. J Urol 165, 93-96.
21. Lackner JE, Schatzl G, Koller A, Mazal P, Waldhoer T, Marberger M & Kratzik C. (2005) Treatment of testicular cancer: influence on pituitary-gonadal axis and sexual function. Urology 66, 402-406.
22. Lackner JE, Märk I, Schatzl G, Marberger M & Kratzik C. (2007) Hypogonadism and androgen deficiency symptoms in testicular cancer survivors. Urology 69, 754-758.
23. Lee DM, O'Neill TW, Pye SR, Silman AJ, Finn JD, Pendleton N et al. (2009) The European Male Ageing Study (EMAS): design, methods and recruitment. Int J Androl 32, 11-24.
24. Maier U. (2001) Hormone profile in the aging man. Wien Med Wochenschr 151, 422-425.
25. Matsumoto AM. (2002) Andropause: clinical implications of the decline in serum testosterone levels with aging in men. J Gerontol A Biol Sci Med Sci 57, M76-M99.
26. Mohr BA, Guay AT, O'Donnell AB & McKinlay JB. (2005) Normal, bound and nonbound testosterone levels in normally ageing men: results from the Massachusetts Male Ageing Study. Clin Endocrinol 62, 64-73.
27. Moller H & Skakkebaek N. (1999) Risk of testicular cancer in subfertile men: case-control study. BMJ 318, 559-562.
28. Nieschlag E, Swerdloff R & Behre HM. (2006) Investigation, treatment and monitoring of late-onset hypogonadism in males: ISA, ISSAM, and EAU recommendations. J Androl 27, 135-137.
29. Nord C, Bjoro T, Ellingsen D, Mykletun A, Dahl O, Klepp O, Bremnes RM, Wist E & Fossa SD. (2003) Gonadal hormones in long-term survivors 10years after treatment for unilateral testicular cancer. Eur Urol 44, 322-328.
30. Palmieri G, Lotrecchiano G, Ricci G, Spiezia R, Lombardi G, Bianco AR & Torino G. (1996) Gonadal function after multimodality treatment in men with testicular germ cell cancer. Eur J Endocrinol 134, 431-436.
31. Petersen PM & Hansen SW. (1999) The course of long-term toxicity in patients treated with cisplatin-based chemotherapy for non-seminomatous germ-cell cancer. Ann Oncol 10, 1475-1483.
32. Petersen PM, Skakkebaek NE & Giwercman A. (1998) Gonadal function in men with testicular cancer: biological and clinical aspects. APMIS 106, 24-34.
33. Petersen PM, Giwercman A, Daugaard G, Rorth M, Petersen JH, Skakkeaek NE, Hansen SW & von der Maase H. (2002) Effect of graded testicular doses of radiotherapy in patients treated for carcinoma-in-situ in the testis. J Clin Oncol 20, 1537-1543.
34. Pont J & Albrecht W. (1997) Fertility after chemotherapy for testicular germ cell cancer. Fertil Steril 68, 1-5.
35. Schmoll HJ, Souchon R, Krege S, Albers P, Beyer J, Kollmannsberger C et al., European Germ Cell Cancer Consensus Group. (2004) European consensus on diagnosis and treatment of germ cell cancer: a report of the European Germ Cell Cancer Consensus Group (EGCCCG). Ann Oncol 15, 1377-1399.
36. Tajar A, Forti G, O'Neill TW, Lee DM, Silman AJ, Finn JD et al. (2010) Characteristics of secondary, primary, and compensated hypogonadism in aging men: evidence from the European Male Ageing Study. J Clin Endocrinol Metab 95, 1810-1818.
37. Thorsen L, Nystad N, Dahl O, Klepp O, Bremens RM, Wist E & Fossa SD. (2003) The level of physical activity in long-term survivors of testicular cancer. Eur J Cancer 39, 1216-1221.
38. Travison TG, Araujo AB, Kupelian V, O'Donnell AB & McKinlay JB. (2007) The relative contributions of aging, health, and lifestyle factors to serum testosterone decline in men. J Clin Endocrinol Metab 92, 549-555.
39. United Kingdom Testicular Cancer Study Group. (1994) Aetiology of testicular cancer: association with congenital abnormalities, age at puberty, infertility, and exercise. BMJ 308, 1393-1399.
40. Urban RJ. (1992) Neuroendocrinology of aging in the male and female. Endocrinol Metab Clin North Am 21, 921-931.
41. Vermeulen A. (2000) Andropause. Maturitas 34, 5-15.
42. Vermeulen A & Kaufman JM. (2002) Diagnosis of hypogonadism in the aging male. Aging Male 5, 170-176.
43. Wang C, Nieschlag E, Swerdloff R, Behre HM, Hellstrom WJ, Gooren LJ et al. (2009) Investigation, treatment and monitoring of late-onset hypogonadism in males. Int J Androl 32, 1-10.
44. Zitzmann M, Faber S & Nieschlag E. (2006) Association of specific symptoms and metabolic risks with serum testosterone in older men. J Clin Endocrinol Metab 91, 4335-4343.